[Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma]
Gonzalez L, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32015000870
Spanish
Authors' recommendations:
The evidence supporting the use of brentuximab vedotin in patients with Hodgkin´s lymphoma as consolidation therapy after stem cell transplant is limited and of moderate quality. The lack of improvement in overall survival limits its recommendation, not being recommended as standard treatment or covered for this indication yet.
The evidence supporting its use in relapsed or refractory to stem cell transplant patients is limited and of low quality. Although its use has shown a high rate of response, sometimes achieving long-term duration, the lack of comparative studies and their impact on survival is its main limitation. In view of the limited therapeutic options and the poor prognosis in these patients, most international societies and health sponsors consider it a valid alternative.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Brentuximab Vedotin
- Hodgkin Disease
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Immunotoxins
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.